Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

APTARGROUP, INC.
Next earnings Jul 30, 2026 · consensus $1.37 EPS, $1.02B rev
Last earnings +0.6% on 2026-04-30
Steady pharma-leaning dispensing-systems compounder with consistent growth and 15% ROE at a fair 20x.
Sources: SEC EDGAR (CIK 0000896622, latest 10-Q filed 2026-05-01) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:31 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The fundamentals carry the rating, but the price is rich (~20% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
AptarGroup makes dispensing, sealing and drug-delivery systems for the pharma, beauty and consumer markets, with the high-value pharma segment (nasal sprays, injectables, inhalation devices) anchoring its quality. The track record is one of dependable compounding: revenue rose 5.4% to $3.78B in FY2025 and has climbed every year from $3.23B in FY2021, while net income grew 4.9% to $393M (up from $244M in FY2021) and diluted EPS rose 6.5% to $5.89. Margins are solid and stable for a packaging company — 24.0% gross, 13.3% operating, 10.4% net — and return on equity is a healthy 14.7%.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.23B | $3.32B | $3.49B | $3.58B | $3.78B |
| Gross profit | — | — | — | — | — |
| Operating income | $347M | $379M | $404M | $496M | $501M |
| Net income | $244M | $239M | $284M | $375M | $393M |
| Diluted EPS | $3.61 | $3.59 | $4.25 | $5.53 | $5.89 |
| Net margin | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1482 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 8 sales
| 2026-06-15 | Gandhi Aditya CAO | Award | 2.66K | |
| 2026-06-09 | Prieur Marc Segment President | Sell | 4.55K @ $115.53 | $526K |
| 2026-06-09 | Prieur Marc Segment President | Sell | 447.00 @ $116.08 | $51.9K |
| 2026-06-04 | Vinczeller Shiela Chief Human Resources Officer | Sell | 2.96K @ $112.36 | $332K |
| 2026-06-04 | Vinczeller Shiela Chief Human Resources Officer | Sell | 385.00 @ $113.52 | $43.7K |
| 2026-06-04 | Vinczeller Shiela Chief Human Resources Officer | Sell | 213.00 @ $114.53 | $24.4K |
| 2026-05-26 | Gong Xiangwei President, Asia | Sell | 4.20K @ $116.13 | $488K |
| 2026-05-21 | Tlili Hedi Segment President | Tax | 688.00 @ $116.50 | $80.2K |
| 2026-05-07 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Sell | 422.00 @ $123.38 | $52.1K |
| 2026-05-07 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Exercise | 842.00 @ $111.38 | $93.8K |
| 2026-05-07 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Sell | 842.00 @ $123.45 | $104K |
| 2026-05-06 | Marey-Semper Isabel Director | Award | 1.33K |